降钙素基因相关肽（CGRP）受体拮抗剂和5-羟色胺1F（5-HT1F）受体激动剂在偏头痛治疗中的应用
CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine.
作者信息
Capi Matilde, De Angelis Valerio, De Bernardini Donatella, De Luca Ottavia, Cipolla Fabiola, Lionetto Luana, Simmaco Maurizio, Martelletti Paolo
机构信息
Laboratory of Clinical Biochemistry, Mass Spectrometry Unit, Sant'Andrea University Hospital, 00185 Rome, Italy.
Department of Clinical and Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.
出版信息
J Clin Med. 2021 Apr 1;10(7):1429. doi: 10.3390/jcm10071429.
Abstract
Discovering that calcitonin-related peptide (CGRP) plays a key role in the complex pathophysiology of migraine has allowed us to make great strides in the development of new approaches for acute and preventive treatment. This evidence has led to the development of small molecules antagonist molecules of the CGRP receptor ("gepants") and of a new class of medications called "Ditans". This review presents the data from clinical trials reporting the efficacy, safety, and tolerability of the new drugs used in the treatment of migraines. Evidences show that therapeutic approaches targeted to CGRP have the potential to transform the clinical management of migraine, even though its appropriate place has yet to be determined with accuracy.
摘要
发现降钙素基因相关肽（CGRP）在偏头痛复杂的病理生理学中起关键作用，这使我们在急性和预防性治疗新方法的开发方面取得了巨大进展。这一证据促使了CGRP受体小分子拮抗剂分子（“gepants”）以及一类名为“Ditans”的新型药物的研发。本综述展示了临床试验数据，这些数据报告了用于治疗偏头痛的新药的疗效、安全性和耐受性。证据表明，针对CGRP的治疗方法有可能改变偏头痛的临床管理，尽管其确切的适用位置尚未准确确定。
相似文献
1
CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine.降钙素基因相关肽（CGRP）受体拮抗剂和5-羟色胺1F（5-HT1F）受体激动剂在偏头痛治疗中的应用
J Clin Med. 2021 Apr 1;10(7):1429. doi: 10.3390/jcm10071429.
2
Targeting CGRP and 5-HT Receptors for the Acute Therapy of Migraine: A Literature Review.靶向 CGRP 和 5-HT 受体治疗偏头痛的急性发作：文献综述。
Headache. 2019 Jul;59 Suppl 2:3-19. doi: 10.1111/head.13582.
3
Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk.直击问题核心：偏头痛、曲坦类药物、DHE、二氢麦角胺、CGRP 抗体、第一代/第二代 gepants 以及心血管风险。
Headache. 2019 Sep;59(8):1421-1426. doi: 10.1111/head.13601. Epub 2019 Jul 18.
4
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.降钙素基因相关肽（CGRP）拮抗剂治疗的历史和综述：从转化研究到治疗。
Headache. 2018 Nov;58 Suppl 3:238-275. doi: 10.1111/head.13379. Epub 2018 Sep 22.
5
[Cardiovascular safety of new drugs for the acute and preventive treatment of migraine: gepants and ditans].[用于偏头痛急性和预防性治疗的新药的心血管安全性： gepants类和ditans类药物]
Rev Neurol. 2023 May 1;76(9):295-308. doi: 10.33588/rn.7609.2022238.
6
Gepants for the treatment of migraine.普萘洛尔透皮贴片治疗偏头痛。
Expert Opin Investig Drugs. 2019 Jun;28(6):555-567. doi: 10.1080/13543784.2019.1618830. Epub 2019 May 17.
7
Novel Medications for the Treatment of Migraine.偏头痛治疗的新药。
Headache. 2019 Oct;59(9):1597-1608. doi: 10.1111/head.13661. Epub 2019 Sep 26.
8
Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.用于急性和预防性偏头痛治疗的 gepants：一项叙述性综述。
Brain Sci. 2022 Nov 24;12(12):1612. doi: 10.3390/brainsci12121612.
9
Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine.降钙素基因相关肽拮抗剂在偏头痛治疗中的研究进展。
Neurol Clin. 2021 Feb;39(1):1-19. doi: 10.1016/j.ncl.2020.09.001. Epub 2020 Nov 7.
10
[Gepants and Ditans].[格潘茨和迪坦斯]
Brain Nerve. 2021 Apr;73(4):315-325. doi: 10.11477/mf.1416201762.
引用本文的文献
1
CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine.降钙素基因相关肽（CGRP）拮抗剂与生酮饮食治疗偏头痛。
Medicina (Kaunas). 2024 Jan 15;60(1):163. doi: 10.3390/medicina60010163.
2
New Migraine Drugs for Older Adults.老年人新的偏头痛药物。
Drugs Aging. 2023 Apr;40(4):301-305. doi: 10.1007/s40266-023-01012-w. Epub 2023 Feb 24.
3
Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.用于急性和预防性偏头痛治疗的 gepants：一项叙述性综述。
Brain Sci. 2022 Nov 24;12(12):1612. doi: 10.3390/brainsci12121612.
4
Reaching the Nadir of Medication Overuse in Chronic Migraine.达到慢性偏头痛药物过度使用的低谷。
Int J Environ Res Public Health. 2022 Nov 9;19(22):14696. doi: 10.3390/ijerph192214696.
5
European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure.欧洲头痛联合会（EHF）关于偏头痛发作有效治疗和曲坦类药物治疗失败的共识。
J Headache Pain. 2022 Oct 12;23(1):133. doi: 10.1186/s10194-022-01502-z.
6
Applying a biopsychosocial model to migraine: rationale and clinical implications.应用生物心理社会模式于偏头痛：原理与临床意义。
J Headache Pain. 2022 Aug 11;23(1):100. doi: 10.1186/s10194-022-01471-3.
7
Ditans: a new prospective for the therapy of migraine attack?二氢麦角胺：偏头痛发作治疗的新展望？
Neurol Sci. 2022 Sep;43(9):5709-5716. doi: 10.1007/s10072-022-06260-z. Epub 2022 Jul 11.
8
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.降钙素基因相关肽（CGRP）靶向单克隆抗体和拮抗剂在偏头痛中的应用：当前证据和原理。
BioDrugs. 2022 May;36(3):341-358. doi: 10.1007/s40259-022-00530-0. Epub 2022 Apr 27.
9
Headache Medicine Grand Challenge: Headache: A New Frontier, A New Challenge.头痛医学重大挑战：头痛：新领域，新挑战。
Front Pain Res (Lausanne). 2021 Aug 9;2:690683. doi: 10.3389/fpain.2021.690683. eCollection 2021.
10
Serotonin receptors in epilepsy: Novel treatment targets?癫痫中的血清素受体：新的治疗靶点？
Epilepsia Open. 2022 Jun;7(2):231-246. doi: 10.1002/epi4.12580. Epub 2022 Feb 2.
本文引用的文献
1
Lasmiditan mechanism of action - review of a selective 5-HT agonist.拉米替坦作用机制——一种选择性 5-HT 激动剂的综述。
J Headache Pain. 2020 Jun 10;21(1):71. doi: 10.1186/s10194-020-01132-3.
2
Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?金纳单抗，降钙素基因相关肽受体拮抗剂：在偏头痛治疗中有何作用？
Curr Opin Neurol. 2020 Jun;33(3):309-315. doi: 10.1097/WCO.0000000000000806.
3
Ubrogepant: First Approval.乌布格列净：首次批准。
Drugs. 2020 Feb;80(3):323-328. doi: 10.1007/s40265-020-01264-5.
4
Ubrogepant for the treatment of migraine.乌布列泮治疗偏头痛。
Expert Opin Pharmacother. 2020 May;21(7):755-759. doi: 10.1080/14656566.2020.1721462. Epub 2020 Feb 3.
5
Profiling lasmiditan as a treatment option for migraine.分析 lasmiditan 作为偏头痛治疗选择的特性。
Expert Opin Pharmacother. 2020 Feb;21(2):147-153. doi: 10.1080/14656566.2019.1694004. Epub 2019 Nov 25.
6
Current and emerging evidence-based treatment options in chronic migraine: a narrative review.慢性偏头痛的当前和新兴循证治疗选择：叙事评价。
J Headache Pain. 2019 Aug 30;20(1):92. doi: 10.1186/s10194-019-1038-4.
7
Fremanezumab for the preventive treatment of migraine in adults.佛来美纳单抗治疗成人偏头痛的预防性治疗。
Expert Rev Clin Pharmacol. 2019 Aug;12(8):741-748. doi: 10.1080/17512433.2019.1635452. Epub 2019 Jun 26.
8
Optimising migraine treatment: from drug-drug interactions to personalized medicine.优化偏头痛治疗：从药物相互作用到个体化医学。
J Headache Pain. 2019 May 17;20(1):56. doi: 10.1186/s10194-019-1010-3.
9
Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.降钙素基因相关肽调节剂——一种新型偏头痛治疗药物类别的历史与复兴。
Headache. 2019 Jun;59(6):951-970. doi: 10.1111/head.13510. Epub 2019 Apr 25.
10
Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.抗降钙素基因相关肽（CGRP）和抗 CGRP 受体单克隆抗体作为偏头痛治疗药物。基于病理生理学假说推测其安全性特征存在潜在差异。
Peptides. 2019 Jun;116:16-21. doi: 10.1016/j.peptides.2019.04.012. Epub 2019 Apr 21.
Zotero 插件